TY - JOUR
T1 - Personalized cancer therapy
T2 - A publicly available precision oncology resource
AU - Kurnit, Katherine C.
AU - Bailey, Ann M.
AU - Zeng, Jia
AU - Johnson, Amber M.
AU - Shufean, M. A.
AU - Brusco, Lauren
AU - Litzenburger, Beate C.
AU - Sanchez, Nora S.
AU - Khotskaya, Yekaterina B.
AU - Holla, Vijaykumar
AU - Simpson, Amy
AU - Mills, Gordon B.
AU - Mendelsohn, John
AU - Bernstam, Elmer
AU - Shaw, Kenna
AU - Meric-Bernstam, Funda
N1 - Funding Information:
B. Litzenburger is a Senior Somatic Scientist in QIAGEN. G.B. Mills reports receiving a commercial research grant from Adelson Medical Research Foundation, AstraZeneca, Critical Outcome Technologies, Komen Research Foundation, Nanostring, Breast Cancer Research Foundation, Karus, Illumina, Takeda/Millenium Pharmaceuticals, Pfizer; has received speakers bureau honoraria from Symphogen, MedImmune, AstraZeneca, ISIS Pharmaceuticals, Lilly, Novartis, ImmunoMet, Allostery, Tarveda, Pfizer; has ownership interest (including patents) in Catena Pharmaceuticals, PTV Ventures, Spindletop Ventures, Myriad Genetics, ImmunoMet; and is a consultant/advisory board member for, Adventist Health, AstraZeneca, Provista Diagnostics, Signalchem Lifesciences, Symphogen, Lilly, Novartis, Tarveda, Tau Therapeutics, Allostery, Catena Pharmaceuticals, Critical Outcome Technologies, ISIS Pharmaceuticals, Immunomet, Takeda/Millenium, MedImmune, Precision Medicine. E.V. Bern-stam has received speakers bureau honoraria from Roche. No potential conflicts of interest were disclosed by the other authors.
Funding Information:
This work was supported in part by 1U01 CA180964 (to F. Meric-Bernstam and E. Bernstam), NIH Research Training Grant T32 CA101642 (to K.C. Kurnit), The Cancer Prevention and Research Institute of Texas (RP150535 to A.M. Bailey, J. Zeng, A.M. Johnson, B.C. Litzenburger, N.S. Sanchez, Y.B. Khotskaya, V. Holla, J. Mendelsohn, E. Bernstam, K. Shaw, and F. Meric-Bernstam), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (to A.M. Bailey, J. Zeng, A.M. Johnson, M.A. Shufean, B.C. Litzenburger, N.S. Sanchez, Y.B. Khots-kaya, V. Holla, A. Simpson, J. Mendelsohn, K. Shaw, and F. Meric-Bernstam), NCATS Grant UL1 TR000371 (Center for Clinical and Translational Sciences; to E. Bernstam and F. Meric-Bernstam), The Bosarge Family Foundation (to G.B. Mills and F. Meric-Bernstam), and the MD Anderson Cancer Center Support Grant (P30 CA016672).
Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - High-throughput genomic and molecular profiling of tumors is emerging as an important clinical approach. Molecular profiling is increasingly being used to guide cancer patient care, especially in advanced and incurable cancers. However, navigating the scientific literature to make evidence-based clinical decisions based on molecular profiling results is overwhelming for many oncology clinicians and researchers. The Personalized Cancer Therapy website (www. personalizedcancertherapy.org) was created to provide an online resource for clinicians and researchers to facilitate navigation of available data. Specifically, this resource can be used to help identify potential therapy options for patients harboring oncogenic genomic alterations. Herein, we describe how content on www.personalized cancertherapy.org is generated and maintained. We end with case scenarios to illustrate the clinical utility of the website. The goal of this publicly available resource is to provide easily accessible information to a broad oncology audience, as this may help ease the information retrieval burden facing participants in the precision oncology field. Cancer Res; 77(21); e123–6. 2017 AACR.
AB - High-throughput genomic and molecular profiling of tumors is emerging as an important clinical approach. Molecular profiling is increasingly being used to guide cancer patient care, especially in advanced and incurable cancers. However, navigating the scientific literature to make evidence-based clinical decisions based on molecular profiling results is overwhelming for many oncology clinicians and researchers. The Personalized Cancer Therapy website (www. personalizedcancertherapy.org) was created to provide an online resource for clinicians and researchers to facilitate navigation of available data. Specifically, this resource can be used to help identify potential therapy options for patients harboring oncogenic genomic alterations. Herein, we describe how content on www.personalized cancertherapy.org is generated and maintained. We end with case scenarios to illustrate the clinical utility of the website. The goal of this publicly available resource is to provide easily accessible information to a broad oncology audience, as this may help ease the information retrieval burden facing participants in the precision oncology field. Cancer Res; 77(21); e123–6. 2017 AACR.
UR - http://www.scopus.com/inward/record.url?scp=85034948516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034948516&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-17-0341
DO - 10.1158/0008-5472.CAN-17-0341
M3 - Article
C2 - 29092956
AN - SCOPUS:85034948516
SN - 0008-5472
VL - 77
SP - e123-e126
JO - Cancer Research
JF - Cancer Research
IS - 21
ER -